Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARE

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 61,329 shares of the biopharmaceutical company’s stock, valued at approximately $1,411,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Aquatic Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 79.1% during the third quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company’s stock worth $5,759,000 after purchasing an additional 84,559 shares during the period. Thornburg Investment Management Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $2,083,000. Aberdeen Group plc lifted its holdings in shares of Ultragenyx Pharmaceutical by 94.3% during the third quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock worth $29,288,000 after buying an additional 472,600 shares in the last quarter. WCM Investment Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 36.9% during the third quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company’s stock worth $8,747,000 after buying an additional 77,640 shares in the last quarter. Finally, Rafferty Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 93.0% during the third quarter. Rafferty Asset Management LLC now owns 156,484 shares of the biopharmaceutical company’s stock worth $4,707,000 after buying an additional 75,388 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Stock Down 1.3%

RARE stock opened at $23.39 on Friday. The company has a market cap of $2.30 billion, a PE ratio of -3.83 and a beta of 0.39. The business has a 50-day simple moving average of $23.22 and a 200 day simple moving average of $26.12. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period last year, the firm earned ($1.57) EPS. On average, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.62 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RARE shares. HC Wainwright dropped their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Weiss Ratings raised Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Canaccord Genuity Group dropped their target price on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $59.88.

Insiders Place Their Bets

In related news, insider John Richard Pinion sold 10,029 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $228,661.20. Following the completion of the transaction, the insider owned 110,026 shares of the company’s stock, valued at $2,508,592.80. The trade was a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the transaction, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 117,262 shares of company stock valued at $2,687,403 over the last 90 days. 5.20% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.